Total submissions: 21
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000079000 | SCV000110869 | benign | not specified | 2012-07-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000029527 | SCV000285004 | benign | Cystic fibrosis | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000079000 | SCV000304492 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Laboratory for Molecular Medicine, |
RCV000079000 | SCV000538671 | benign | not specified | 2018-09-14 | criteria provided, single submitter | clinical testing | The p.Ser1235Arg variant in CFTR is classified as benign because it has been ide ntified in 0.9% (87/10124) of Ashkenazi Jewish chromosomes and 0.7% (939/125536) of European chromosomes, including 4 homozygotes, by gnomAD (http://gnomad.broa dinstitute.org). ACMG/AMP Criteria applied: BA1. |
ARUP Laboratories, |
RCV000755234 | SCV000602980 | uncertain significance | not provided | 2023-11-10 | criteria provided, single submitter | clinical testing | The CFTR c.3705T>G; p.Ser1235Arg variant (rs34911792) is historically considered to be mildly pathogenic due to its prevalence in patients diagnosed with mild respiratory disorders (Rene 2011) or chronic pancreatitis (Hamoir 2013, Steiner 2011, Weiss 2005). However, genotype-phenotype studies indicate that the variant is observed at similar frequencies between affected and asymptomatic individuals (LaRusch 2014, Monaghan 2000, Rene 2011, Sosnay 2013). Functional studies also indicate no defect in CFTR maturation or chloride transport activity (Sosnay 2013, Van Goor 2014). The variant is listed in ClinVar (Variation ID: 35872) and is observed in the general population at an overall frequency of 0.5% (1,409/279,632 alleles, including 4 homozygotes) in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.531). Current evidence indicates that this variant, when present with a pathogenic CFTR variant on the opposite chromosome, is not associated with classic cystic fibrosis. However, it remains uncertain whether it may contribute to the clinical phenotype in individuals with milder CFTR-related disease (e.g., an isolated presentation of pancreatitis, congenital bilateral absence of the vas deferens, or mild lung disease). References: Hamoir C et al. Clinical and morphological characteristics of sporadic genetically determined pancreatitis as compared to idiopathic pancreatitis: higher risk of pancreatic cancer in CFTR variants. Digestion. 2013; 87(4):229-39. PMID: 23751316. LaRusch J et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 2014; 10(7):e1004376. PMID: 25033378. Monaghan K et al. Frequency and clinical significance of the S1235R mutation in the cystic fibrosis transmembrane conductance regulator gene: results from a collaborative study. Am J Med Genet. 2000; 95(4):361-5. PMID: 11186891. Rene C et al. p.Ser1235Arg should no longer be considered as a cystic fibrosis mutation: results from a large collaborative study. Eur J Hum Genet. 2011; 19(1):36-42. PMID: 20717170. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45(10):1160-7. PMID: 23974870. Steiner B et al. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat. 2011; 32(8):912-20. PMID: 21520337. Van Goor F et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014; 13(1):29-36. PMID: 23891399. Weiss F et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut. 2005; 54(10):1456-60. PMID: 15987793. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000755234 | SCV000888089 | benign | not provided | 2022-02-04 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000029527 | SCV001137494 | likely benign | Cystic fibrosis | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000029527 | SCV001182478 | likely benign | Cystic fibrosis | 2019-01-26 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000755234 | SCV001246822 | likely benign | not provided | 2024-09-01 | criteria provided, single submitter | clinical testing | CFTR: BS2 |
Illumina Laboratory Services, |
RCV001163789 | SCV001325863 | uncertain significance | CFTR-related disorder | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Johns Hopkins Genomics, |
RCV000029527 | SCV001425415 | benign | Cystic fibrosis | 2020-04-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000029527 | SCV001737318 | likely benign | Cystic fibrosis | 2021-06-10 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV001801912 | SCV002529715 | benign | Hereditary pancreatitis | 2020-10-24 | criteria provided, single submitter | curation | |
MGZ Medical Genetics Center | RCV000029527 | SCV002581076 | uncertain significance | Cystic fibrosis | 2022-07-26 | criteria provided, single submitter | clinical testing | |
Clinical Genetics Laboratory, |
RCV000079000 | SCV005197470 | benign | not specified | 2024-03-13 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000029527 | SCV000052179 | benign | Cystic fibrosis | 2013-10-29 | no assertion criteria provided | clinical testing | |
Genetic Services Laboratory, |
RCV000079000 | SCV000150651 | likely benign | not specified | no assertion criteria provided | clinical testing | Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. | |
Natera, |
RCV000029527 | SCV001460115 | benign | Cystic fibrosis | 2020-01-11 | no assertion criteria provided | clinical testing | |
Institute of Reproductive Genetics, |
RCV001642238 | SCV001860328 | likely pathogenic | Obstructive azoospermia | 2021-08-23 | flagged submission | clinical testing | |
Zotz- |
RCV003333727 | SCV004041742 | uncertain significance | Congenital bilateral aplasia of vas deferens from CFTR mutation | 2023-10-09 | no assertion criteria provided | clinical testing | |
Zotz- |
RCV000029527 | SCV004099324 | uncertain significance | Cystic fibrosis | 2023-10-30 | no assertion criteria provided | clinical testing |